Investigating novel mechanisms of Translesion Synthesis (TLS) regulation in cancer Public Deposited

Downloadable Content

Download PDF
Last Modified
  • March 22, 2019
  • Holk, Alicia
    • Affiliation: School of Medicine, Curriculum in Genetics and Molecular Biology
  • Cells are subjected to a range of DNA damaging agents from intrinsic, environmental, and therapeutic sources. The ability to cope with DNA damage is essential for maintaining genomic stability and preventing disease. Trans-lesion Synthesis(TLS) is a mechanism by which cells tolerate DNA damage by utilizing flexible, albeit error-prone, polymerases to bypass DNA lesions. Here we show that aberrantly expressed cancer testes antigen, Melanoma-Associated Antigen 4 (MAGE-A4), is a unique regulator of TLS in many neoplastic cells, demonstrating a novel mechanism for both mutagenesis and therapy-resistant cancer. Owing to its role in chemoresistance, TLS represents an appealing pathway for targeted cancer therapies. As an initial step in the drug discovery process we have identified small molecule inhibitors which target the essential interaction between TLS Polymerase Eta and mono-ubiquitinated PCNA. Taken together, we have identified a new mechanism for conferring tumorigenic phenotypes and initiated efforts to target this pathway for therapeutic purposes.
Date of publication
Resource type
Rights statement
  • In Copyright
  • Vaziri, Cyrus
  • Ramsden, Dale
  • Sekelsky, Jeff
  • Major, Ben
  • Master of Science
Degree granting institution
  • University of North Carolina at Chapel Hill Graduate School
Graduation year
  • 2016

This work has no parents.